Home / Trigger atlas / Medications & treatments / Methotrexate (low dose)

Medications · Updated 2026-10-30 · Editorial review in progress

Methotrexate hair loss in rheumatoid arthritis: what the trials show

Also searched as: methotrexate hair lossmethotrexate hair thinning rheumatoid arthritisMTX hair loss

A meta-analysis of randomized trials of weekly low-dose methotrexate with folic or folinic acid estimated alopecia at 1.0%–4.9%; in a UK cohort of 1,069 people with early RA, alcohol use was linked to higher odds of alopecia.

No consistent week-by-week window is published for this, so it is not on the calculator.

The timeline

StageWhen (typically)What's happening
Typical drug-shed onset2–4 months after a start or dose changeDermNet: with telogen effluvium from drugs, hair loss usually becomes evident after 2–4 months. [DermNet]

Low dose vs chemo dose

Weekly low dose (RA, psoriasis)High-dose chemotherapy
How often1.0%–4.9% alopecia in RCTs [Arthritis]Anagen hair loss is common with chemotherapy [DermNet]
MechanismUsually telogen shedding [DermNet]Growing hairs stop [DermNet]

Who noticed it more in the UK study

Normal vs. warning signs

Commonly normal
  • Mild diffuse thinning
  • No patches
Warning signs — get checked
  • Patches or smooth bald spots
  • Scalp pain, redness, burning or scaling
  • Loss of eyebrows, eyelashes or body hair
  • Mouth ulcers, fever or unusual bruising — contact your rheumatology team
Find a trichologist →

What may help

Related triggers

Frequently asked questions

How common is methotrexate hair loss?

Randomized trials put alopecia at 1.0%–4.9% on weekly low-dose methotrexate.

Does folic acid help methotrexate hair loss?

The trials in the meta-analysis all used folic or folinic acid; whether to change your dose is a question for your rheumatologist.

When does methotrexate hair loss start?

Drug-related shedding usually becomes evident 2–4 months after a start or dose change, per DermNet.

Sources

  1. Arthritis Care & Research, 2020. Low-Dose Methotrexate and Mucocutaneous Adverse Events: Systematic Review and Meta-Analysis of RCTs
  2. Rheumatology (Oxford), 2022. Rates and predictors of methotrexate-related adverse events in early rheumatoid arthritis (RAMS, n=1069)
  3. DermNet. Alopecia from drugs